公司资产和项目 - Relay Therapeutics在2022年第三季度末的现金、现金等价物和投资达到了11亿美元[6] - 公司拥有3个处于临床阶段的资产和5个公开披露的项目[8] RLY-2608项目 - RLY-2608针对PI3KαPAN，预计每年可治疗约8-51K患者[9] - RLY-2608具有对突变型PI3Kα的生物化学选择性，相对于野生型PI3Kα，其选择性为11,000倍[36] - RLY-2608在整个激酶组中具有选择性，仅抑制PI3Kα，并具有对突变型PI3Kα的优先抑制[37] RLY-4008项目 - RLY-4008是一种高度选择性和不可逆抑制剂，对Pan-FGFR具有强大的抑制作用[17] - RLY-4008在Cholangiocarcinoma (CCA)患者中展示出显著的疗效，包括FGFR2融合阳性患者[18] - RLY-4008在FGFR2突变和扩增的肿瘤中展示出肿瘤回归的潜力，包括BC和非CCA患者[25] Fusion+ CCA FGFRi-Naïve患者 - Fusion+ CCA FGFRi-Naïve患者在70 mg QD剂量下，显示出88%的最佳RECIST变化，包括15名患者中的14名确认部分缓解[20] - Fusion+ CCA FGFRi-Naïve患者在所有剂量下显示出63%的最佳RECIST变化，大多数患者表现出部分缓解[22] - Fusion+ CCA FGFRi-Naïve患者在所有剂量下，92%的患者出现肿瘤缩小，大部分患者表现出部分缓解[22] 公司战略和合作 - Relay Tx与Genentech进行全球合作，开展GDC-1971的临床试验[50] - Relay Therapeutics的Dynamo™平台能力和专业知识不断扩展，支持早期管线的深度和多样化[52]

ESMO Disclosure Call Materials September 2022 Confidential | © 2022 Relay Therapeutics 1 Disclaimer This presentation contains forward-looking statements and information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of historical facts contained in this presentation, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, ...

Company Presentation August 2022 Confidential | © 2022 Relay Therapeutics 1 Disclaimer This presentation contains forward-looking statements and information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of historical facts contained in this presentation, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, object ...

Company Presentation May 2022 Confidential | © 2022 Relay Therapeutics 1 Disclaimer This presentation contains forward-looking statements and information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of historical facts contained in this presentation, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objective ...

Company Presentation February 2022 Confidential | © 2022 Relay Therapeutics 1 Disclaimer This presentation contains forward-looking statements and information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of historical facts contained in this presentation, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, obje ...

January 2022 RELAY® THERAPE U TI C S 40th Annual J.P. Morgan Healthcare Conference Company Presentation Confidential | © 2022 Relay Therapeutics 1 Disclaimer This presentation contains forward-looking statements and information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of historical facts contained in this presentation, including statements regarding our strategy, future financial ...

Company Presentation January 2021 Confidential | © 2021 Relay Therapeutics 1 Disclaimer 2 This presentation contains forward-looking statements and information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of historical facts contained in this presentation, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, obj ...